|
Thursday 14th September 2023 |
Text too small? |
Cannasouth Limited (NZX: CBD ) has exported to Australia its first commercial shipment of its high-purity cannabidiol (CBD) isolate, a cannabis-based, active pharmaceutical ingredient (API). This is a first for Aotearoa New Zealand’s medicinal cannabis industry.
This CBD isolate was manufactured in New Zealand to PIC/s Good Manufacturing Practice (GMP) standards and verified by the Medicinal Cannabis Agency. This first shipment is the forerunner of greater volumes of API exports for the local industry, signalling the demand for high-quality, GMP certified cannabis-based APIs on the international stage.
This signals the next growth phase for Cannasouth and the medicinal cannabis industry.
-ENDS-
No comments yet
SML - Synlait ELT update
August 17th Morning Report
CMO - Preliminary result and dividend
GXH - Green Cross Health Limited (GXH) CEO Resignation
MEL - Meridian Energy monthly operating report for July 2026
August 14th Morning Report
VHP - Managed Investment Scheme 2026 Annual Report
PYS - Annual Meeting and Director Nominations
SCT - Scott Expects Record FY26 as 2030 Strategy Gains Momentum
PGW - Positive PGW Results in Improving Markets